NCT01742988 · Interventional trial
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
Overall registry status Completed
Phase 1
Conditions Double-expressor Lymphoma (DEL), Double-hit Lymphoma (DHL), High-grade B-cell Lymphoma (HGBL), Lymphoma, Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Relapsed Lymphoma, Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Lymphoma, Triple-hit Lymphoma (THL)
Delaware Valley sites
- Hospital of the University of Pennsylvania · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory